Japanese pump makers largely unaffected by earthquake

Japanese pump makers largely unaffected by earthquake

NEWS Japanese pump makers Franklin Electric to largely unaffected by acquire majority stake earthquake in Turkey’s Impo S ome of Japan’s largest pu...

82KB Sizes 1 Downloads 77 Views

NEWS

Japanese pump makers Franklin Electric to largely unaffected by acquire majority stake earthquake in Turkey’s Impo

S

ome of Japan’s largest pump manufacturers have reported no serious damage to their production facilities following the earthquake in north-eastern Japan on 11 March 2011 and the subsequent tsunami. Ebara Corp’s manufacturing facilities were only slightly affected by the earthquake and the company restarted operations on 14 March. Ebara is working as a group to provide an uninterrupted flow of products and services to customers and has put a system in place to assist the affected areas and to quickly restore damaged equipment and systems. Torishima Pump Mfg Co Ltd reports no employee injuries or casualties and no damage to its production facilities located in Osaka, in western Japan, approximately 700 km from the earthquake region. There was also no serious damage at the company’s sales offices. The rolling blackouts are also not affecting Torishima’s production facilities. The company is donating ¥30 million to the relief efforts. Tsurumi Mfg Co Ltd says that its manufacturing plant and staff in Japan are unaff fected by the recent earthquake and tsunami. Tsurumi has its head office in Osaka and a pump manufacturing plant in Kyoto. Meanwhile Iwaki’s production facilities in Saitama and Miharu need some repairs, but did not suffer serious damage, and they have restarted production. • ITT Corp has authorised US$100 000 from its emergency response fund to support Mercy Corps and its local partner, Peace Winds, with on-the-ground relief efforts in Japan. ITT will also match all employee donations, up to US$5000 for a maximum of US$10 000 per employee, to Japan relief efforts. Pentair Inc is donating US$200 000 to fund portable water treatment systems in Japan. The Pentair donation will support Water Missions International, which is sending 14 Living Water Treatment Systems to Japan. The systems can produce 200 000 gallons of potable water per day, serving the drinking water needs of 65 000 people.

For further information, visit www.ebara.co.jp, www.torishima.co.jp, www.tsurumipump.co.jp, www.iwakipumps.jp, www.itt.com and www.pentair.com

16

Pump Industry Analyst

F

ranklin Electric Co Inc has reached a definitive agreement to buy 80% of the outstanding shares of Turkish pumping systems manufacturer Ýmpo Motor Pompa Sanayi ve Ticaret AS (Impo). Based in Izmir, Impo specialises in the design, manufacture and sale of groundwater pumping systems and has annual sales of approximately US$25 million. Franklin Electric expects the transaction to close in the second quarter of 2011. For further information, visit www.franklin-electric.com and www.impoas.com

Weir funds research centre at University of Strathclyde

T

he Weir Group PLC is investing almost £2 million in a dedicated research facility at The University of Strathclyde’s newly established Technology and Innovation Centre (TIC) in Glasgow. The Weir Advanced Research Centre (WARC) is expected to provide a pipeline of new product innovation and significant improvements in existing product performance. Weir will fund the centre with an initial £1.9 million investment over three years, with funding for year four onwards to be agreed each year under a rolling programme. Weir will also create four PhD studentships per year. Weir’s chief executive, Keith Cochrane said: “The University of Strathclyde is a leading international technological University and Weir is delighted to be strengthening the long-standing partnership we have enjoyed with Strathclyde through the creation of the WARC.” The £89 million TIC will bring together academics, researchers and project managers from the University of Strathclyde and its industrial partners. TIC founding partners include Scottish and Southern Energy, ScottishPower and Weir.

For further information, visit www.weir.co.uk and www.strath.ac.uk

Editorial Office: Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom Tel: +44 (0)1865 843695 Fax: +44 (0)1865 843933 Web: www.pumpindustryanalyst.com Editor: Roisin Reidy E-mail: [email protected] Production Support Manager: Lin Lucas E-mail: [email protected] Publisher: Greg Valero E-mail: [email protected] Subscription Information An annual subscription to Pump Industry Analyst includes 12 issues and online access for up to 5 users. Prices: 1176 for all European countries & Iran US$1319 for all countries except Europe and Japan ¥156 345 for Japan (Prices valid until 31 December 2011) To subscribe send payment to the address above. Tel: +44 (0)1865 843687/Fax: +44 (0)1865 834971/ Email: [email protected], or via www.pumpindustryanalyst.com. Subscriptions run for 12 months, from the date payment is received. Periodicals postage is paid at Rahway, NJ 07065, USA. Postmaster send all USA address corrections to: Pump Industry Analyst, 365 Blair Road, Avenel, NJ 07001, USA Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; phone: (+44) 1865 843830, fax: (+44) 1865 853333, email: permissions@ elsevier.com. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 7508400, fax: (978) 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 207 436 5931; fax: (+44) 207 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Perr mission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Digitally Produced by Mayfield Press (Oxford) LImited 02167

March 2011